Curanex Pharmaceuticals Inc Common Stock
Veridion Score
Composite trend over time
Why is CURX moving today?
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CURX.
CURX insider activity
Curanex Pharmaceuticals Inc Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for CURX.
CURX contract awards, year to date.
Public federal awards linked to this ticker.
CURX lobbying filings, year to date.
Registered lobbying filings matched to Curanex Pharmaceuticals Inc Common Stock.